SiBone (NASDAQ:SIBN – Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $18.91, for a total transaction of $378,200.00. Following the completion of the transaction, the director owned 16,057 shares of the company’s stock, valued at $303,637.87. This trade represents a 55.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
SiBone Stock Down 2.7%
SIBN opened at $18.64 on Friday. The business’s fifty day simple moving average is $18.09 and its 200 day simple moving average is $15.55. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The stock has a market cap of $826.68 million, a PE ratio of -54.82 and a beta of 0.70.
SiBone (NASDAQ:SIBN – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The firm had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. As a group, research analysts expect that SiBone will post -0.4 earnings per share for the current fiscal year.
Hedge Funds Weigh In On SiBone
Wall Street Analyst Weigh In
Several analysts have issued reports on SIBN shares. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. UBS Group lifted their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. TD Cowen lifted their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, Truist Financial reiterated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.
View Our Latest Stock Report on SiBone
About SiBone
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
- Five stocks we like better than SiBone
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
